Today: 20 May 2026
UOB share price slips as MAS turns slightly hawkish — what investors watch next
30 January 2026
2 mins read

UOB share price slips as MAS turns slightly hawkish — what investors watch next

Singapore, Jan 30, 2026, 14:51 SGT — Regular session

  • UOB shares dropped 0.6% on Friday, while Singapore bank stocks showed a mixed performance.
  • MAS left policy unchanged but lifted its inflation forecast for 2026, rattling some risk bets.
  • Attention shifts to UOB’s Feb. 24 earnings for clues on margins and credit costs.

United Overseas Bank Ltd (UOB) shares dipped 0.6% to S$38.41 on Friday, slipping 24 Singapore cents from Thursday’s finish. Trading remained uneven following a solid rally in local banks. The stock fluctuated between S$38.40 and S$38.65. Meanwhile, DBS dropped 0.8% and OCBC inched up 0.2%.

The pullback is significant since Singapore’s banks have been carrying much of the weight for local equities. Investors are now wrestling with how “higher for longer” inflation could impact earnings, trying not to get ahead of themselves on valuations.

This comes as the earnings season is about to heat up. UOB won’t report for several weeks yet, but investors are already focusing intently on guidance—particularly around loan quality and the direction of margins.

On Thursday, the Monetary Authority of Singapore held its exchange-rate policy steady but raised its 2026 core and headline inflation forecasts to 1.0%–2.0%, up from 0.5%–1.5%, citing upside risks to growth and inflation. OCBC economist Selena Ling described the central bank’s tone as “a tad more hawkish and less dovish,” while Maybank’s Chua Hak Bin noted “simmering inflation pressures emerging.” Reuters

Brokers pushed prices higher, only to pull them back again. According to The Business Times, UOB’s consensus target price climbed to S$37.26, even as the stock lingered above that mark after hitting a record S$39.50 last week. Macquarie’s Jayden Vantarakis labeled UOB a “catch-up play,” while JPMorgan downgraded its rating to “underweight.”

Traders see it plainly: the rally already baked in plenty of good news, so minor changes in the macro outlook can spark profit-taking. UOB’s Friday move felt more like repositioning than a reaction to new company developments.

Feb. 24 is the next key date. UOB announced in an exchange filing that it will publish its full-year 2025 financial results ahead of the market open that day.

Investors are keenly eyeing any shift in the bank’s forecast for net interest margin — the difference between earnings on loans and expenses on deposits — along with updates on credit costs and fee income. Signals about dividends will also draw attention, especially following the stock’s strong rally this month.

UOB has flagged a potential dip in margins as the rate cycle shifts. Back in November, the bank forecast its full-year 2026 net interest margin to land between 1.75% and 1.80%, which is lower than its 2025 estimate. It also projected total credit costs to range from 25 to 30 basis points.

There is a downside risk. Should inflation remain stubborn and policy tighten further later this year, funding costs might outpace asset yields. A shaky global economy could also trigger a swift rise in credit provisions, particularly for a regionally-focused lender like UOB.

Investors are now eyeing UOB’s report due Feb. 24, with keen interest in what management reveals about margins and loan stress as 2026 approaches.

Stock Market Today

  • Sea Limited (NYSE:SE) Valuation Under Scrutiny After 46% One-Year Share Decline
    May 20, 2026, 10:05 AM EDT. Sea Limited (NYSE:SE), active across e-commerce, digital financial services, and digital entertainment in Southeast Asia and Latin America, has seen its stock fall by 46.26% over the past year. Despite recent share price weakness, some analysts argue the stock trades 36.6% below a $137.64 fair value estimate, buoyed by strong revenue growth from Shopee, Monee, and Garena platforms. Key drivers include accelerating mobile internet penetration, youth digital literacy, and shifts toward cashless payments supporting loan book expansion and improved monetization. Market watchers debate whether this dip offers a buying opportunity or reflects tempered growth prospects, especially as Shopee faces competitive pressures. Investors should weigh Sea's potential for earnings growth against market realities and execution risks.

Latest articles

Vida CEO Steps In as $15 Million AI IPO Hits Reality Check

Vida CEO Steps In as $15 Million AI IPO Hits Reality Check

20 May 2026
Vida Global Inc. raised $15 million in its May 18 IPO, selling 3.75 million shares at $4 each, but the stock closed at $2.29 on Tuesday. CEO Lyle Pratt bought 312,900 shares for about $1.19 million, according to a Form 4 filing. Vida reported 2025 revenue of $551,383 and a net loss of $2.9 million. The company’s shares trade on NYSE American and NYSE Texas under the symbol VIDA.
TJX Shares Rise Premarket As T.J. Maxx Parent Raises Outlook

TJX Shares Rise Premarket As T.J. Maxx Parent Raises Outlook

20 May 2026
TJX raised its fiscal 2027 sales, earnings, and buyback targets after first-quarter comparable sales rose 6% and net income hit $1.3 billion. Shares climbed 3.6% in premarket trading. The company cited higher fuel costs as a drag on its full-year forecast. Marmaxx, HomeGoods, and TJX Canada all posted strong sales growth.
ImmunityBio in the Spotlight with Patents and BCG Deal Ahead of the Open

ImmunityBio Faces FDA Decision on Bladder-Cancer Application, Risk Remains

20 May 2026
The FDA accepted ImmunityBio’s application to expand Anktiva’s use with BCG in papillary-only, BCG-unresponsive non-muscle invasive bladder cancer, setting a Jan. 6, 2027 decision date. ImmunityBio reported $44.2 million in first-quarter net product revenue and held $380.9 million in cash and equivalents. Shares last traded at $7.76, down 2.8%. The filing is supported by data from 80 patients in a Phase 2/3 trial.
Snowflake stock slides nearly 8% in software rout; traders brace for next catalyst
Previous Story

Snowflake stock slides nearly 8% in software rout; traders brace for next catalyst

GSK share price dips in London as Exdensur rollout and Feb 4 results loom
Next Story

GSK share price dips in London as Exdensur rollout and Feb 4 results loom

Go toTop